-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cell cycle checkpoints give cells time to repair DNA damage and chromatin damage before cell division, thereby avoiding replication disasters
Wee1 kinase inhibitor Adavosertib can stop cell cycle arrest and cause cell death
The study adopted a 3+3 dose escalation design, 21 days as a course of treatment, and Adavosertib was taken once a day on Days 1-5 and Days 8-12
Adavosertib plasma concentration changes
Adavosertib plasma concentration changesA total of 42 patients were recruited
The dose of Adavosertib is 300 mg once daily
Treatment remission
Treatment remissionSix patients (14%) achieved a confirmed partial remission: 4 cases of ovarian cancer and 2 cases of endometrial cancer
Six patients (14%) achieved a confirmed partial remission: 4 cases of ovarian cancer and 2 cases of endometrial cancer
Adverse reactions
Adverse reactionsThe most common adverse reactions are gastrointestinal and blood; dose-limiting toxicity is grade 4 hematological toxicity and grade 3 fatigue
In summary, the study evaluated the efficacy of Adavosertib RPh2D once a day for advanced solid tumors.
Original source:
Original source:Naoko Takebe, et al.
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
in this message